Kindstar Globalgene Technology, Inc. (HKG:9960)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
0.9600
-0.0300 (-3.03%)
Jun 18, 2026, 4:08 PM HKT
Market Cap957.23M -26.1%
Revenue (ttm)1.04B +0.6%
Net Income-65.37M
EPS-0.07
Shares Out 997.12M
PE Ration/a
Forward PEn/a
Dividend0.10 (9.90%)
Ex-Dividend DateJun 9, 2026
Volume357,500
Open0.9900
Previous Close0.9900
Day's Range0.9300 - 0.9900
52-Week Range0.9300 - 1.7500
Beta0.61
AnalystsStrong Buy
Price Target3.39 (+253.13%)
Earnings DateAug 28, 2026

About HKG:9960

Kindstar Globalgene Technology, Inc., an investment holding company, provides clinical testing services in the People’s Republic of China and Mainland China. It operates through nine segments: Hematology Testing. Genetic Diseases and Rare Diseases, Infectious Diseases, Oncology, Neurology, Maternity-Related Diseases, Routine Testing, CROs and R&D Project, and Others. The company offers esoteric testing services for hematology, oncology, neuroscience and infectious diseases. It also engages in product development and technical services; reagent ... [Read more]

Sector Healthcare
Founded 2003
Employees 3,100
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9960
Full Company Profile

Financial Performance

In 2025, HKG:9960's revenue was 933.57 million, an increase of 0.65% compared to the previous year's 927.57 million. Losses were -58.74 million, 7.61% more than in 2024.

Financial numbers in CNY Financial Statements